Polycystic ovary syndrome and endometrial cancer

Seminars in Reproductive Medicine

Volumn 26, Issue 1, 2008, Pages 62-71

  Navaratnarajah, Ramesan ^a   Pillay, Ouma C ^a   Hardiman, Paul ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Endometrial carcinoma; Endometrial hyperplasia; Polycystic ovaries; Polycystic ovary syndrome

Indexed keywords

ANDROGEN RECEPTOR; CYSTEINE RICH PROTEIN 61; ESTROGEN; ESTROGEN RECEPTOR; INSULIN; LUTEINIZING HORMONE; METFORMIN; MIFEPRISTONE; OSTEOPONTIN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN DLG7; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANOVULATION; ARTICLE; CHRONIC DISEASE; CLINICAL FEATURE; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; FEMALE; HORMONAL THERAPY; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INCIDENCE; LOW DRUG DOSE; OBESITY; OVARY POLYCYSTIC DISEASE; RISK REDUCTION;

ANDROGENS; CARCINOMA, ENDOMETRIOID; ENDOMETRIAL NEOPLASMS; ESTROGENS; FEMALE; HUMANS; INCIDENCE; INSULIN; LUTEINIZING HORMONE; POLYCYSTIC OVARY SYNDROME; PROGNOSIS;

EID: 38149108993     PISSN: 15268004     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-992926     Document Type: Article

References (60)

1. Speert H. Carcinoma of the endometrium in young women. Surg Gynecol Obstet 1949;88:332-336
2. Hardiman P, Pillay OS, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet 2003;361:1810-1812
3. Velazquez EM, Mendoza SG, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinaemia, insulin resistance, hyperandrogenaemia, and systolic blood pressure, whilst facilitating normal menses and pregnancy. Metabolism 1994;43:647-654
4. The Rotterdam ESHRE/ASRM Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-47
5. Jackson RL, Dockerty MB. The Stein-Leventhal syndrome: analysis of 43 cases with special reference to association with endometrial carcinoma. Am J Obstet Gynecol 1957;73:161-173
6. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181-189
7. Jemal A, Thomas A, Murray T, Thun M. American Cancer Society Cancer Statistics, 2002. CA Cancer J Clin 2002;52:23-47
8. Coleman MP, Rachet B, Woods LM, et al. Trends and socioeconomic inequalities in cancer survival in England and Wales up to 2001. Br J Cancer 2004;90:1367-1373
9. Bray F, dos Santos Silva I, Moller H, Weiderpass E. Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention. Cancer Epidemiol Biomarkers Prev 2005;14:1132-1142
10. Ramzy I, Nisker JA. Histologic study of ovaries of young women with endometrial carcinoma. Am J Clin Pathol 1979;71:253-256
11. Soliman PT, Oh JC, Schmeler KM. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol 2005;105:575-580
12. Dockerty MB, Lovelady B, Foust GT, et al. Carcinoma of corpus uteri in young women. Am J Obstet Gynecol 1951;61:966-981
13. Coulam CB, Annegers JF, Kranz JS. Chronic anovulation syndrome and associated neoplasia. Obstet Gynecol 1983;61:403-407
14. Escobedo LG, Lee NC, Peterson HB, Wingo PA. Infertility-associated endometrial cancer risk may be limited to specific subgroups in infertile women. Obstet Gynecol 1991;77:124-128
15. Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol 1984;64:417-420
16. Dahlgren E, Friberg LG, Johansson S. Endometrial carcinoma: ovarian dysfunction-a risk factor in young women. Eur J Obstet Gynecol Reprod Biol 1991;41:143-150
17. Konishi I, Koshiyama M, Mandai M, et al. Increased expression of LH/hCG receptors in endometrial hyperplasia and carcinoma in anovulatory women. Gynecol Oncol 1997;65(2):273-280
18. Ho SP, Tan KT, Pang MW, Ho TH. Endometrial hyperplasia and the risk of endometrial carcinoma. Singapore Med J 1997;38:11-15
19. Pierpoint T, McKeigue P, Isaacs AJ, et al. Mortality of women with polycystic ovary syndrome at long term follow up. J Clin Epidemiol 1998;51:581-586
20. Wild S, Pierpoint T, Jacobs H, McKeigue P. Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum Fertil 2000;3:101-105
21. Pillay OC, Wong Te Fong LF, Crow JC, et al. The association between polycystic ovaries and endometrial cancer. Hum Reprod 2006;21(4):924-929
22. Luque-Ramirez M, Alvarez-Blasco F, Mendieta-Azcona C, Botella-Carretero JI, Escobar-Morreale HF. Obesity is the major determinant of the abnormalities in blood pressure found in young women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:2141-2148
23. Cibula D, Cifkova R, Fanta M, Poledne R, Zivny J, Skikoba J. Increased of NIDDM, arterial hypertension and coronary artery disease in perimenopausal women with a history of PCOS. Hum Reprod 2000;15:785-789
24. Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril 2002;77:1095-1105
25. Friberg E, Orsini N, Mantzoros CS, Wolk A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 2007;50:1365-1374
26. Friberg E, Mantzoros CS, Wolk A. Physical activity and risk of endometrial cancer: a population-based prospective cohort study. Cancer Epidemiol Biomarkers Prev 2006;15:2136-2140
27. Glintborg D, Henriksen JE, Andersen M, et al. Prevalence of endocrine diseases and abnormal glucose tolerance tests in 340 Caucasian premenopausal women with hirsutism as the referral diagnosis. Fertil Steril 2004;82:1570-1579
28. Chang SC, Lacey JV, Brinton LA, et al. Lifetime weight history and endometrial cancer risk by type of menopausal hormone use in the NIH-AARP diet and health study. Cancer Epidemiol Biomarkers Prev 2007;16:723-730
29. Furberg AS, Thune I. Metabolic abnormalities (hypertension, hyperglycemia and overweight), lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian cohort. Int J Cancer 2003;104:669-676
30. Birdsall MA, Farquhar CM. Polycystic ovaries in pre and post-menopausal women. Clin Endocrinol (Oxf) 1996;44:269-276
31. Winters SJ, Talbott E, Guzick DS, Zborowski J, McHugh KP. Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome. Fertil Steril 2000;73:724-729
32. Lukanova A, Lundin E, Micheli A, et al. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer 2004;108:425-432
33. Nagamani M, Hannigan EV, Dillard EA, Van Dinh T. Ovarian steroid secretion in postmenopausal women with and without endometrial cancer. J Clin Endocrinol Metab 1986;62:508-512
34. Potischman N, Hoover RN, Brinton LA, et al. Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst 1996;88:1127-1135
35. Schemeler K, Soliman PT, Sun CC, Slomovitz BM, Gershenson DM, Lu KH. Endometrial cancer in young, normal-weight women. Gynecol Oncol 2005;99:388-392
36. Jafari K, Javaheri G, Ruiz G. Endometrial adenocarcinoma and the Stein-Leventhal syndrome. Obstet Gynecol 1978;51:97-100
37. Farhi DC, Nosanchuk J, Silverberg SG. Endometrial adenocarcinoma in women under 25 years of age. Obstet Gynecol 1986;68:741-745
38. Nakanishi T, Ishikawa H, Suzuki Y, Inoue T, Nakamura S, Kuzuya K. Association between menopausal state and endometrial cancer. Int J Gynecol Cancer 2001;11:483-487
39. Pillay OC, Te Fong LF, Crow JC, et al. The association between polycystic ovaries and endometrial cancer. Hum Reprod 2006;21:924-929
40. Soslow RA, Shen P, Chung MH, Isacson C, Baergen RN. Cyclin D1 expression in high-grade endometrial carcinomas-association with histologic subtype. Int J Gynecol Pathol 2000;19:329-334
41. Giangrande PH, McDonnell DP. The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene. Rec Prog Horm Res 1999;54:291-313
42. Masafumi Koshiyama KI, Mandai M. Increased expression of LH/hCG receptors in endometrial hyperplasia and carcinoma in anovulatory women. Gynecol Oncol 1997;65:273-280
43. Dabizzi S, Noci I, Borri P, et al. Luteinizing hormone increases human endometrial cancer cells invasiveness through activation of protein kinase A. Cancer Res 2003;63:4281-4286
44. Baillargeon J-P, Carpentier A. Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity. Fertil Steril 2007;88:886-893
45. Pasquali R, Gamberi A. Polycystic ovary syndrome: a multifaceted disease from adolescence to adult age. Ann N Y Acad Sci 2006;1092:158-174
46. Nagamani M, Stuart CA. Specific binding and growth-promoting activity of insulin in endometrial cancer cells in culture. Am J Obstet Gynecol 1998;179:6-12
47. Bershtein LM, Gamaiunova VB, Kvachevskaia IO. The nature of hyperinsulinaemia (insulin resistance) in endometrial carcinoma: of plasma levels of insulin and c-peptide. Vopr Onkol 2000;46:191-195
48. Soliman PT, Wu D, Tortolero-Luna G, et al. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer 2006;106:2376-2381
49. Bik W, Baranowska-Bik A, Wolinska-Witort E. The relationship between metabolic status and levels of adiponectin and ghrelin in lean women with polycystic ovary syndrome. Gynecol Endocrinol 2007;23:325-331
50. Tada A, Sasaki H, Nakamura J, Yoshihama M, Terashima Y. Aromatase activity and the effect of estradiol and testosterone on DNA synthesis in endometrial carcinoma cell lines. J Steroid Biochem Mol Biol 1993;44:661-666
51. Apparao KB, Lovely LP, Gui Y. Elevated endometrial androgen receptor expression in women with polycystic ovarian syndrome. Biol Reprod 2002;66:297-304
52. Pillay OC, Leonard A, Sharkey A, Catalano R, Hardiman P. Endometrial gene expression in women with PCOS. Human Reprod 2005;20(Supp 1):20
53. Chen Y, Wang Y, Li M. Expression of apoptosis regulatory protein bcl-2 and bax in endometrium of polycystic ovary syndrome. Zhonghua Fu Chan Ke Za Zhi 1999;34:652-654
54. MacLaughlan SD, Palomino WA, Mo B, et al. Endometrial expression of Cyr61: a marker of estrogenic activity in normal and abnormal endometrium. Obstet Gynecol 2007;110:146-154
55. Orio F Jr, Palomba S, Cascella T, et al. Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. J Clin Endocrinol Metab 2005;90:6072-6076
56. Palomba S, Russo T, Orio F Jr, et al. Uterine effects of metformin administration in anovulatory women with polycystic ovary syndrome. Hum Reprod 2006;21:457-465
57. Costello MF, Shrestha B, Eden J, Johnson NP, Sjoblom P. Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. Hum Reprod 2007;22:1200-1209
58. Cameron ST, Critchley HOD, Thong KJ, et al. Effects of daily low dose mifepristone on endometrial maturation and proliferation. Hum Reprod 1996;11:2518-2526
59. Narvekar N, Cameron S, Critchley HOD, Lin S, Cheng L, Baird DT. Low-dose mifepristone inhibits endometrial proliferation and up-regulates androgen receptor. J Clin Endocrinol Metab 2004;89:2491-2497
60. Di Spiezio Sardo A, Radhakrishnan S. Endometrial carcinoma on continuous combined HRT: case report and literature review. Maturitas 2004;48:171-175